Carmen Di Giovanni

Dr. Carmen Di Giovanni

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2013 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
Antonio LavecchiaAntonio Lavecchia
Antonio Lavecchia
Carmen Di GiovanniCarmen Di Giovanni
Carmen Di Giovanni
Virtual screening (VS) is a powerful technique for identifying hit molecules as starting points for medicinal chemistry. The number of methods and softwares which use the ligand and target-based VS approaches is increasing at a rapid pace. What, however, are the real advantages and disadvantages of the VS technology and how applicable is it to drug discovery projects? This review provides a comprehensive appraisal of several VS approaches currently available. In the first part of this work, an overview of the recent progress and advances in both ligand-based VS (LBVS) and structurebased VS (SBVS) strategies highlighting current problems and limitations will be provided. Special emphasis will be given to in silico chemogenomics approaches which utilize annotated ligand-target as well as protein-ligand interaction databases and which could predict or reveal promiscuous binding and polypharmacology, the knowledge of which would help medicinal chemists to design more potent clinical candidates with fewer side effects. In the second part, recent case studies (all published in the last two years) will be discussed where the VS technology has been applied successfully. A critical analysis of these case studies provides a good platform in order to estimate the applicability of various VS strategies in the new lead identification and optimization.

1 January 2012 in Mini-Reviews in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
Antonio LavecchiaAntonio Lavecchia
Antonio Lavecchia
Carmen Di GiovanniCarmen Di Giovanni
Carmen Di Giovanni
ENEttore Novellino
Ettore Novellino
The cell division cycle 25 (CDC25) family of proteins is a group of highly conserved dual-specificity phosphatases. They are key regulators of normal cell division and the cell response to DNA damage, and play a fundamental role in transitions between cell cycle phases during normal cell division, via the activation of CdK/cyclin complexes. Their abnormal expression, detected in a number of tumors, often correlated with a poor clinical prognosis, implies that their dysregulation is involved in malignant transformation. Thus, inhibition of these proteins represents an attractive therapeutic target in oncology, as evidenced from many patents and papers published on the subject in recent years. Hence, this review aims to provide an overview of recent developments in the field of CDC25 phosphatase inhibitor design since 2008.

18 February 2010 in Expert Opinion on Therapeutic Patents
Verified
Journal Article
Closed access
Antonio LavecchiaAntonio Lavecchia
Antonio Lavecchia
Carmen Di GiovanniCarmen Di Giovanni
Carmen Di Giovanni
ENEttore Novellino
Ettore Novellino
(2010). Inhibitors of Cdc25 phosphatases as anticancer agents: a patent review. Expert Opinion on Therapeutic Patents: Vol. 20, No. 3, pp. 405-425. doi: 10.1517/13543771003623232

1 June 2011 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
Antonio LavecchiaAntonio Lavecchia
Antonio Lavecchia
Carmen Di GiovanniCarmen Di Giovanni
Carmen Di Giovanni
ENEttore Novellino
Ettore Novellino
The signal transducers and activators of transcription (STATs) include a class of cytoplasmic signaling proteins whose role in the regulation of cell growth and survival is mediated by phosphorylation of a critical tyrosine residue within the STAT protein. This occurs in response to cytokines and growth factors modulating the expression of specific target genes. In particular, phosphorylation induces STAT:STAT dimer formation between two monomers, via reciprocal phosphoTyr (pTyr)-SH2 domain interactions. To date, seven members of the STAT family, all with different roles, have been identified in mammals. After dimerization, phosphorylated STATs enter the nucleus and, working co-ordinately with other transcriptional co-activators and transcription factors, induce increased transcriptional initiation. In healthy human and animal cells, ligand-dependent activation of STATs is a transient process, lasting for several minutes to several hours. In contrast, in many cancerous cell lines and tumors, where growth factor dysregulation is frequently at the heart of cellular transformation, the STAT proteins (in particular STAT1, 3 and 5) are persistently tyrosine-phosphorylated or activated; abnormal levels of STAT3 activation have been observed in breast, ovarian, prostate, hematological and head and neck cancer cell lines. Thus, in this review, we examine the most important classes of agents designed to disrupt STAT3 signaling, with particular regard to STAT3 dimerization inhibitors, which could play a significant role in the future of cancer and adjuvant cancer therapies.

1 January 2006 in Pharmacological Research
Verified
Journal Article
Closed access
Carmen Di GiovanniCarmen Di Giovanni
Carmen Di Giovanni
VAVincenzo Arcoraci
Vincenzo Arcoraci
LGL Gambardella
L Gambardella
LSL Sautebin
L Sautebin

1 May 2012 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Antonio LavecchiaAntonio Lavecchia
Antonio Lavecchia
Carmen Di GiovanniCarmen Di Giovanni
Carmen Di Giovanni
APAda Pesapane
Ada Pesapane
NMNunzia Montuori
Nunzia Montuori
PRPia Ragno
Pia Ragno
ENEttore Novellino
Ettore Novellino